{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:32:13Z","timestamp":1773221533142,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.leukres.2025.108113","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:06:36Z","timestamp":1758978396000},"page":"108113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluating complete response\/remission rate as a surrogate endpoint in relapsed\/refractory chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"158","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Disher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Craigie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena K.","family":"Perna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Aronitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loic","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2025.108113_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic lymphocytic Leukemia\/Small lymphocytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"2","key":"10.1016\/j.leukres.2025.108113_bib2","first-page":"S11","article-title":"Management of relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Woyach","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.108113_bib3","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2021-148472","article-title":"Real-world treatment patterns and outcomes of patients with chronic lymphocytic leukemia (CLL) receiving first-line (1L) therapy in the United States (US)","volume":"138","author":"Mato","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2025.108113_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2023.03.010","article-title":"Treatment discontinuation patterns for patients with chronic lymphocytic leukemia in real-world settings: results from a multi-center international study","volume":"23","author":"Shadman","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"12","key":"10.1016\/j.leukres.2025.108113_bib5","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.108113_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/hematology.2020000086","article-title":"Standard treatment approaches for relapsed\/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy","author":"Moreno","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2025.108113_bib7","unstructured":"BREYANZI\u00ae (lisocabtagene maraleucel) [package insert]. Bothell, WA: Juno Therapeutics Inc., a Bristol-Myers Squibb Company; June 2025."},{"key":"10.1016\/j.leukres.2025.108113_bib8","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. Accessed 25 April 2024. \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic\u3009."},{"issue":"16","key":"10.1016\/j.leukres.2025.108113_bib9","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.leukres.2025.108113_bib10","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-10-0570","article-title":"U.S. Food and drug administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab","volume":"16","author":"Lemery","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2025.108113_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00277-024-05666-3","article-title":"On behalf of the FIRE investigators group. Final results on effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study","volume":"104","author":"Dartigeas","year":"2025","journal-title":"Ann. Hematol."},{"issue":"22","key":"10.1016\/j.leukres.2025.108113_bib12","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V128.22.2045.2045","article-title":"Attainment of complete remission is significantly associated with longer survival outcomes in relapsed\/refractory (R\/R) CLL: a meta-analysis","volume":"128","author":"Ektare","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108113_bib13","unstructured":"United States Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. Guidance for industry. Accessed 11 December 2024. \u3008https:\/\/www.fda.gov\/media\/71195\/download\u3009."},{"key":"10.1016\/j.leukres.2025.108113_bib14","unstructured":"United States Food and Drug Administration. Surrogate endpoint resources for drug and biologic development. Accessed 25 April 2024. \u3008https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development\u3009."},{"key":"10.1016\/j.leukres.2025.108113_bib15","unstructured":"Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-. Validity of surrogate endpoints in oncology: Executive summary of rapid report A10-05, Version 1.1. 21 November 2021. Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK198799\/\u3009."},{"key":"10.1016\/j.leukres.2025.108113_bib16","unstructured":"Bujkiewicz S., Achana F., Papanikos T., Riley R.D., Abrams K.R. NICE DSU Techinal Support Document 20: Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints. Version 2. Report by the Decision Support Unit. Accessed 16 February 2024. \u3008https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/multivariate-meta-analysis\u3009."},{"issue":"1","key":"10.1016\/j.leukres.2025.108113_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/biostatistics\/kxm023","article-title":"An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown","volume":"9","author":"Riley","year":"2008","journal-title":"Biostatistics"},{"key":"10.1016\/j.leukres.2025.108113_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"issue":"17","key":"10.1016\/j.leukres.2025.108113_bib19","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M","article-title":"Meta-analysis for the evaluation of potential surrogate markers","volume":"16","author":"Daniels","year":"1997","journal-title":"Stat. Med."},{"key":"10.1016\/j.leukres.2025.108113_bib20","unstructured":"Debray T., de Jong V. metamisc: Meta-analysis of diagnosis and prognosis research studies. R package version 0.4.0. Accessed 11 December 2024. \u3008https:\/\/CRAN.R-project.org\/package=metamisc\u3009."},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.13061","volume":"167","author":"Awan","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.14464","article-title":"Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia","volume":"176","author":"Robak","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2025.108113_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1470-2045(11)70242-X","article-title":"Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial","volume":"12","author":"Elter","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108113_bib25","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-012-1660-6","article-title":"Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia","volume":"92","author":"Niederle","year":"2013","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2025.108113_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","article-title":"Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial","volume":"58","author":"Robak","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.leukres.2025.108113_bib28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.2009.26.4556","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2025.108113_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.leukres.2025.108113_bib30","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified t cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib31","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2025.108113_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15_","key":"10.1016\/j.leukres.2025.108113_bib33","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/jco.2014.32.15_suppl.3028","article-title":"Phase 2 open-label study of MEDI-551 and bendamustine versus rituximab and bendamustine in adults with relapsed or refractory CLL","volume":"32","author":"Gladstone","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.leukres.2025.108113_bib34","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib35","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.leukres.2025.108113_bib36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood.2019003570","article-title":"Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors","volume":"135","author":"Strati","year":"2020","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.leukres.2025.108113_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/cancers15020507","article-title":"Characteristics and clinical outcomes of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma receiving ibrutinib for \u22655 years in the RESONATE-2 study","volume":"15","author":"Woyach","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \"trial-level\" surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.leukres.2025.108113_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.leukres.2025.108113_bib40","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood-2018-01-824177","article-title":"MRD negativity as a surrogate for PFS in CLL?","volume":"131","author":"Thompson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108113_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1130617","article-title":"The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials","volume":"13","author":"Fisher","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.108113_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000287","article-title":"Minimal residual disease assessment in CLL: ready for use in clinical routine?","volume":"3","author":"F\u00fcrstenau","year":"2019","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.leukres.2025.108113_bib43","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2023-178597","article-title":"Endpoint surrogacy in chronic lymphocytic leukemia: a pooled analysis of the German CLL study group","volume":"142","author":"Simon","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2025.108113_bib44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.24.01192","article-title":"Endpoint surrogacy in first-line chronic lymphocytic leukemia","volume":"43","author":"Simon","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2025.108113_bib45","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2024.2122","article-title":"Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"10","author":"Rios-Olais","year":"2024","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2025.108113_bib46","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3109\/10428194.2015.1122783","article-title":"Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia","volume":"57","author":"\u00d6sterborg","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2025.108113_bib47","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2025.108113_bib48","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.leukres.2025.108113_bib49","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2016-10-748210","article-title":"Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"129","author":"Ghia","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.108113_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134783","article-title":"Umbralisib plus ublituximab (U2) is superior to obinutuzumab plus chlorambucil (O+Chl) in patients with treatment na\u00efve (TN) and relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): results from the phase 3 Unity-CLL study","volume":"136","author":"Gribben","year":"2020","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:10:00Z","timestamp":1773144600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S0145212625006034"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108113","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating complete response\/remission rate as a surrogate endpoint in relapsed\/refractory chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108113"}}